BACKUP PLAN ONESTEP 1.5 MG — DIN 02433532
LEVONORGESTREL : 1.5 MG · APOTEX INC · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is BACKUP PLAN ONESTEP?
BACKUP PLAN ONESTEP 1.5 MG contains LEVONORGESTREL : 1.5 MG. It is listed in the Health Canada Drug Product Database under DIN 02433532, held by APOTEX INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 07-Jun-2016. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is BACKUP PLAN ONESTEP used for?
Emergency contraception to prevent pregnancy within 72 hours of unprotected intercourse or known/suspected contraceptive failure. Not for routine use.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Levonorgestrel cost around the world?
Levonorgestrel is listed on 14 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Bahrain publishes a retail (max); Brazil publishes a preco fabrica (ex-factory ceiling). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Spain | PVP con IVA (public price) | 26 | 26 | EUR███.██ |
| South Africa | single exit price | 20 | 20 | ZAR███.██ |
| Australia | ex-manufacturer | 16 | 17 | AUD███.██ |
| Brazil | preco fabrica (ex-factory ceiling) | 11 | 14 | BRL███.██ |
| Sweden | AIP (pharmacy purchase price) | 7 | 14 | SEK███.██ |
| Norway | max AUP (pharmacy retail) | 9 | 12 | NOK███.██ |
| Saudi Arabia | public | 4 | 6 | SAR███.██ |
| Morocco | PPV (public price) | 3 | 4 | MAD███.██ |
| United States | acquisition | 1 | 3 | USD███.██ |
| Bahrain | retail (max) | 2 | 2 | BHD███.██ |
| United Kingdom | hospital | 2 | 2 | GBP███.██ |
| Romania | max producer price | 2 | 2 | RON███.██ |
| United Arab Emirates | public | 1 | 1 | AED███.██ |
| Greece | producer price (ex-factory) | 1 | 1 | EUR███.██ |
124 pack listings across 105 brand entries and 13 price bases, refreshed 08 Sep 2026. Ranges span every Levonorgestrel pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Levonorgestrel in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
10 holders have a Canadian DIN containing Levonorgestrel, across 13 DINs, of which 4 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| APOTEX INC | 2 | 1 | BACKUP PLAN, BACKUP PLAN ONESTEP | Sourceable in Canada |
| FOUNDATION CONSUMER HEALTHCARE, LLC | 2 | 1 | PLAN B | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 1 | 1 | MYSTEP | Sourceable in Canada |
| MYLAN PHARMACEUTICALS ULC | 1 | 1 | CONTINGENCY ONE | Sourceable in Canada |
| LABORATOIRE HRA PHARMA | 2 | 0 | NORLEVO | No marketed DIN |
| ACTAVIS PHARMA COMPANY | 1 | 0 | NEXT CHOICE | No marketed DIN |
| JAI PHARMA LIMITED | 1 | 0 | CONTINGENCY | No marketed DIN |
| LUPIN LIMITED | 1 | 0 | LEVONORGESTREL TABLETS, 0.75MG | No marketed DIN |
| PERRIGO INTERNATIONAL | 1 | 0 | OPTION 2 | No marketed DIN |
| TEVA CANADA LIMITED | 1 | 0 | TEVA-LEVONORGESTREL | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 1.5 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | Single tablet packaged in PVC/PVDC - aluminum foil blister. |
| Storage | Not explicitly detailed in provided text (standard pharmaceutical storage typically 15-30°C, but section 11 is listed in TOC but not fully provided in snippet). |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Levonorgestrel |
|---|---|
| ATC code | G03AD01 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02433532 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2433532 |
| Brand name | BACKUP PLAN ONESTEP |
| Generic / active ingredient | LEVONORGESTREL : 1.5 MG |
| Market authorization holder | APOTEX INC |
| Health Canada schedule | NON-PRESCRIPTION DRUGS |
| ATC code | G03AD01 |
| ATC anatomical main group | G — Genito-urinary system and sex hormones |
| ATC therapeutic subgroup | G03AD |
| Current status | MARKETED |
| Status date | 07-Jun-2016 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
One 1.5 mg tablet taken orally as soon as possible, but within 72 hours after unprotected intercourse. If vomiting occurs within 2 hours of dosing, a replacement dose may be warranted.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to levonorgestrel or any ingredient; known or suspected pregnancy; undiagnosed abnormal vaginal bleeding.
Warnings and precautions
No protection against HIV/STIs. Not an abortifacient. Potential reduced efficacy with increased BMI. Monitor for ectopic pregnancy if abdominal pain occurs or menses is delayed.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
4 of 13 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| CONTINGENCY ONE | 1.5 MG | TABLET | MYLAN PHARMACEUTICALS ULC | MARKETED | 02425009 |
| MYSTEP | 1.5 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | 02548461 |
| PLAN B | 1.5 MG | TABLET | FOUNDATION CONSUMER HEALTHCARE, LLC | MARKETED | 02293854 |
| BACKUP PLAN | 0.75 MG | TABLET | APOTEX INC | CANCELLED PRE MARKET | 02430177 |
| CONTINGENCY | 0.75 MG | TABLET | JAI PHARMA LIMITED | CANCELLED PRE MARKET | 02410230 |
| LEVONORGESTREL TABLETS, 0.75MG | 0.75 MG | TABLET | LUPIN LIMITED | CANCELLED PRE MARKET | 02431033 |
| NEXT CHOICE | 0.75 MG | TABLET | ACTAVIS PHARMA COMPANY | CANCELLED POST MARKET | 02364905 |
| NORLEVO | 1.5 MG | TABLET | LABORATOIRE HRA PHARMA | APPROVED | 02322919 |
| NORLEVO | 0.75 MG | TABLET | LABORATOIRE HRA PHARMA | CANCELLED POST MARKET | 02285576 |
| OPTION 2 | 0.75 MG | TABLET | PERRIGO INTERNATIONAL | CANCELLED POST MARKET | 02371189 |
2 · Same class — other molecules in ATC G03AD
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Levonorgestrel | BACKUP PLAN · BACKUP PLAN ONESTEP · CONTINGENCY · CONTINGENCY ONE · +7 more | 13 | 4 | Yes |
| Ulipristal | ELLA | 1 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC G03A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| G03AA | Desogestrel And Estrogen · Drospirenone And Estetrol · Drospirenone And Estrogen · Etynodiol And Estrogen · Levonorgestrel And Estrogen · +4 more | 105 | 46 |
| G03AB | Desogestrel And Estrogen · Dienogest And Estrogen · Levonorgestrel And Estrogen · Norethisterone And Estrogen · Norgestimate And Estrogen · +2 more | 40 | 14 |
| G03AC | Drospirenone · Etonogestrel · Levonorgestrel · Medroxyprogesterone · Norethisterone · +1 more | 13 | 6 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is BACKUP PLAN ONESTEP called?
The same molecule, Levonorgestrel, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Mirena | Latin | Australia, Brazil, Norway, South Africa |
| Kyleena | Latin | Australia, Brazil, Norway, South Africa |
| LEVONORGESTREL | Latin | Brazil |
| Leverette | Latin | Sweden |
| Levonorgestrel/Etinylestradiol Ebb | Latin | Sweden |
| Logynon ED | Latin | Australia, South Africa |
| Microgynon | Latin | Norway |
| Microval | Latin | Morocco, South Africa |
| NORLEVO | Latin | Morocco, South Africa |
| Prionelle | Latin | Sweden |
| Rigevidoncont | Latin | Sweden |
| Avibela | Latin | South Africa |
| DIAD | Latin | Brazil |
| Ekuvor | Latin | South Africa |
| Escapelle Tablet | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.